Navigation Links
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
Date:9/21/2009

e world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Forward-Looking Statements

This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Sept. 21, 2009 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candid
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), ... the development of brachytherapy devices and medical isotopes ... it has filed a de novo ... for marketing clearance for its patented Y-90 RadioGel(TM) ... Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... Agency (EMA) of the Marketing Authorization Application (MAA) ... recently granted the company,s request for accelerated assessment, ... regulatory review time.   The MAA, ...
(Date:12/24/2014)... ALEXANDRIA, Va. , Dec. 23, 2014 /PRNewswire-USNewswire/ ... stringent diastolic blood pressure target for people with ... either moderate or high doses of statins, in ... risk management enacted by the American College of ... recommendations are reflected in the most recent changes ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... will present new data across its portfolio representing ... rare and difficult-to-treat cancers.  These results will be ... for Medical Oncology (ESMO) Congress in Milan, Italy ... http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO) "Pfizer ...
... Oct. 7 Vivaglobin® (subcutaneous immunoglobulin [IgG]) (SCIg) ... treatment-naive patients with primary immunodeficiency (PI) and may ... therapy in the newly diagnosed, according to data ... European Society for Immunodeficiencies. The study found that ...
Cached Medicine Technology:Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 2Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 3Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 4Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 5Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 6Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 7Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 8Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 9Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 10Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 11Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 12Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin® as First-Line Therapy for Primary Immunodeficiency 2Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin® as First-Line Therapy for Primary Immunodeficiency 3Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin® as First-Line Therapy for Primary Immunodeficiency 4
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional ... all of the models at LunaDress.co.uk come with big discounts, up ... wedding veil can turn out to be a most exciting memory ... can always bring surprise to a wedding. On the updated fashion ... choose veils for a big day . , Going out with ...
(Date:12/25/2014)... (HealthDay News) -- Among early stage breast cancer patients ... of one percent will eventually develop leukemia as a ... The finding comes from a review of more than ... and it suggests that the risk for developing treatment-related ... previously thought. "The frequency of bone marrow cancers ...
(Date:12/25/2014)... 25, 2014 “ SmileStix ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... personal stickers. , The old saying goes, “A picture says ... words that can describe a single image, because each picture ...
(Date:12/25/2014)... Parker & Sons, Inc. an industry leader ... quality regarding heating, cooling and plumbing services in the ... the “Queen of Clean” for impressive contractor services in ... over the years for providing outstanding quality customer service ... services for both homeowners and businesses. Linda Cobb, known ...
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
Breaking Medicine News(10 mins):Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3
... issue of American Journal of Preventive Medicine says that there ... ,These conclusions were arrived at by researchers at ... Centers for Disease Control and Prevention. They monitored data of ... Factor Surveillance System survey. This particular survey covered 22 states ...
... appearing in the online journal Cancer says that elderly white ... to develop full blown melanoma regardless of their exposure to ... study found that women in the age group of 50 ... carcinoma or squamous cell carcinoma of the skin, had a ...
... attempt to rapidly eliminate milder strains of avian influenza virus ... been proposed to broaden the target of the European Union ... been taken by agricultural ministers of the 25 different countries ... the proposal, it was agreed to boost the currently existing ...
... into the oral HIV tests which have given false results. ... California and New York health centers. The rapid OraQuick Advance ... minutes. The test had gained popularity as blood samples are ... ,Complaints are being investigated by officials belonging to ...
... Hickok, neuroscientist, professor of cognitive sciences at the University ... The National Institute of //Deafness and Other Communication Disorders ... Health ($2.4 million for 5 years). ,This ... brain converts sound waves into meaningful language. ...
... health hospitals are flooded with patients with psychiatric disorders. The ... 12% in the past 4 years. ,This ... health facilities. ,According to the Australian Institute of ... specialized psychiatric hospitals decreased by 5%. ,But the ...
Cached Medicine News:Health News:Detection of Weak strains of bird flu virus – Target of European Unio 2Health News:$2.4 Million Grant To Unravel The Mystery Of Language Recognition. 2Health News:Community hospitals inundated with Psychiatric care cases (12%) 2
... Grade PRODUCT SPECIFICATIONS Form: Granular, free-flowing powder EEO(-m r ... Point (3%): less than or equal to 35.5C ... 80C Gel Strength (1.5%): greater than or equal ... greater than or equal to 1500 gm/cm 2 ...
... sulfate (SO 4 ) ≤ 6000 mg/kg Cation traces: ... ≤ 10 mg/kg Cr ≤ 10 mg/kg Cu ≤ ... mg/kg Mg ≤ 10 mg/kg Mn ≤ 10 mg/kg ... ≤ 10 mg/kg Zn ≤ 10 mg/kg Special ...
Application: Capable of separating DNA fragments of 50 to 1000 bp on a 3% gel Solubility: water 15 mg/mL, clear, colorless, hot Special grade: for molecular biology Suitab tst: electrophoresis te...
Inquire...
Medicine Products: